There is lab data suggesting an interaction between LYMErix and certain genotypes potentially inducing arthritis, but the initial trial and post market surveillance data did not show any meaningfully elevated arthritis rates. However, post market surveillance was definitely hampered by the limited market uptake, fueled partly by the side effect concern.
Genetic testing/screening should be significantly cheaper today, and the higher prevalence of ticks as a concern would probably mean that LYMErix could probably be a viable product today, even if its arthritis side effect profile was real, as long as it was combined with screening.
There is lab data suggesting an interaction between LYMErix and certain genotypes potentially inducing arthritis, but the initial trial and post market surveillance data did not show any meaningfully elevated arthritis rates. However, post market surveillance was definitely hampered by the limited market uptake, fueled partly by the side effect concern.
Genetic testing/screening should be significantly cheaper today, and the higher prevalence of ticks as a concern would probably mean that LYMErix could probably be a viable product today, even if its arthritis side effect profile was real, as long as it was combined with screening.